Cangrelor in Patients With Acute Myocardial Infarction Undergoing PCI After CPR, Ventilated or Cardiogenic Shock
NCT ID: NCT04611607
Last Updated: 2022-07-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
303 participants
OBSERVATIONAL
2021-05-04
2022-06-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry
NCT04076813
Add-on Cangrelor in STEMI-triggered Cardiac Arrest
NCT03273075
Cangrelor in Comatose Survivors of OHCA Undergoing Primary PCI
NCT04005729
Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size
NCT03043274
Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO
NCT06792643
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study is purely observational; data will be documented retrospectively based on available medical records. No additional data will be collected, no study-related treatment will be initiated.
About 10 - 20 high-volume PCI clinics in Germany treating patients with myocardial infarction are eligible for participation. Participating sites will be given a maximum of 6 months for retrospectively documenting eligible patients.
Eligible are all patients with acute myocardial infarction (STEMI, NSTEMI) who underwent PCI after CRP, ventilated and/or with cardiogenic shock and were treated with cangrelor during index procedure. It is planned to enrol about 400 patients in total. Patient characteristics, procedural details and clinical events occurring during the period between index MI and discharge or death (whichever came first) will be documented based on the relevant existing medical charts of the patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acute Myocardial infarction (NSTEMI or STEMI)
* PCI with stent implantation
* Treatment with cangrelor during index procedure
* At least one of the following criteria:
* CPR prior to PCI
* Cardiogenic shock
* Heart failure with the need for mechanical or non-invasive ventila-tion
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ferrer Internacional S.A.
INDUSTRY
IHF GmbH - Institut für Herzinfarktforschung
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Uwe Zeymer, Prof
Role: PRINCIPAL_INVESTIGATOR
Klinikum Ludwigshafen ; Stiftung IHF Institut für Herzinfarktforschung
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitätsklinikum Graz
Graz, , Austria
Klinik Ottakring
Vienna, , Austria
Fürst-Stirum Klinikum Bruchsal
Bruchsal, , Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, , Germany
Klinikum Leverkusen
Leverkusen, , Germany
Klinikum Ludwigshafen
Ludwigshafen, , Germany
Universitätsklinikum Mannheim
Mannheim, , Germany
Hegau-Bodensee Klinikum Singen
Singen, , Germany
Krankenhaus Maria-Hilf
Stadtlohn, , Germany
Universitätsklinikum Tübingen
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAN-SHOCK
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.